Multiple neuroendocrine carcinoma: a case report_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

LIU Hao ¹ , WU Chengyi ² ,  XU Jigang ¹ , CHEN Juan ³ , WANG Yalan ⁴

1. Department of Thoracic and Breast General Surgery, The People’s Hospital of Bishan Distrct, Chongqing 402760, P. R. China;
2. Department of Endocrinology and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P. R. China;
3. Department of Pathology, The People’s Hospital of Bishan Distrct, Chongqing 402760, P. R. China;
4. Department of Pathology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P. R. China;

Corresponding author：

XU Jigang, Email: xujigangys@163.com

Keywords：

neuroendocrine carcinoma; multidisciplinary team; diagnosis; treatment

DOI：

10.7507/1007-9424.202002076

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To study the diagnosis and treatment of multiple neuroendocrine carcinoma.Method Clinical data of a case of multiple neuroendocrine carcinoma was retrospective analyzed.Results After discussion by a multidisciplinary team (MDT), the patient was diagnosed as multiple neuroendocrine carcinoma with late clinical stage and inoperable. Chemotherapy and radiotherapy were given, which showed significant effects, and the patient died after 1 year of follow-up.Conclusion In the clinical diagnosis and treatment of patients with multiple neuroendocrine carcinoma, MDT cooperative treatment model should be adopted to provide a better treatment program.

Citation： LIU Hao, WU Chengyi, XU Jigang, CHEN Juan, WANG Yalan. Multiple neuroendocrine carcinoma: a case report. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2020, 27(8): 999-1004. doi: 10.7507/1007-9424.202002076 Copy

1.	Pearse AG. The diffuse neuroendocrine system and the apud concept: related “endocrine” peptides in brain, intestine, pituitary, placenta, and anuran cutaneous glands. Med Biol, 1977, 55(3): 115-125.
2.	Inzani F, Petrone G, Fadda G, et al. Cyto-histology in NET: what is necessary today and what is the future? Rev Endocr Metab Disord, 2017, 18(4): 381-391.
3.	盛伟琪. 胃肠胰神经内分泌肿瘤病理诊断的规范和进展. 中国癌症杂志, 2013, 23(6): 401-407.
4.	2013 年中国胃肠胰神经内分泌肿瘤病理诊断共识专家组. 中国胃肠胰神经内分泌肿瘤病理诊断共识 (2013 版). 中华病理学杂志, 2013, 42(10): 691-694.
5.	Tan EH, Tan CH. Imaging of gastroenteropancreatic neuroendocrine tumors. World J Clin Oncol, 2011, 2(1): 28-43.
6.	徐建明. 重视对胃肠胰腺神经内分泌肿瘤的认识. 中华肿瘤杂志, 2012, 34(2): 158-160.
7.	Öberg KE. Gastrointestinal neuroendocrine tumors. Ann Oncol, 2010, 21(Suppl 7): 72-80.
8.	中国临床肿瘤学会神经内分泌肿瘤专家委员会. 中国胃肠胰神经内分泌肿瘤专家共识(2016年版). 临床肿瘤学杂志, 2016, 21(10): 927-946.
9.	张太平, 李建, 赵玉沛. 胰腺神经内分泌肿瘤诊治进展. 中华外科杂志, 2014, 52(9): 706-708.
10.	刘毫, 吴诚义, 吕忠柱. 胰腺神经内分泌肿瘤的综合治疗. 中国普外基础与临床杂志, 2016, 23(3): 369-373.
11.	岑超平, 陈晓, 李冲, 等. 胰腺神经内分泌肿瘤诊治进展. 肿瘤基础与临床, 2015, 28(2): 178-179, 180.
12.	Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol, 2018, 31(12): 1770-1786.
13.	李洁, 孙宇, 吴佳怿. 胰腺和胃肠道来源神经内分泌肿瘤分类—2018 IARC/WHO分类框架共识解读. 肿瘤综合治疗电子杂志, 2018, 4(4): 16-20.
14.	Scoazec JY, Couvelard A, Réseau TENpath. Classification of pancreatic neuroendocrine tumours: changes made in the 2017 WHO classification of tumours of endocrine organs and perspectives for the future. Ann Pathol, 2017, 37(6): 444-456.
15.	郭鑫, 任思谦, 原春辉. 胰腺神经内分泌肿瘤综合诊治进展. 临床外科杂志, 2019, 27(12): 1094-1098.
16.	Inzani F, Petrone G, Rindi G. The new World Health Organization classification for pancreatic neuroendocrine neoplasia. Endocrinol Metab Clin North Am, 2018, 47(3): 463-470.
17.	王旭, 于鑫淼, 毛晓韵, 等. 乳腺神经内分泌癌的诊断及治疗. 中国实用外科杂志, 2016, 36(7): 743-747.
18.	Halvorson SA, Gilbert E, Hopkins RS, et al. Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome. J Gen Intern Med, 2013, 28(11): 1525-1529.
19.	程悦, 黄子星, 宋彬. 胰腺神经内分泌肿瘤影像研究现状及进展. 中国普外基础与临床杂志, 2020, 27(4): 489-493.
20.	Moertel CG, Kvols LK, O’Connell MJ, et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer, 1991, 68(2): 227-232.
21.	Yalcin S. Advances in the systemic treatment of pancreatic neuroendocrine tumors. Cancer Treat Rev, 2011, 37(2): 127-132.
22.	Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC Study. Ann Oncol, 2013, 24(1): 152-160.
23.	Pavel ME, Wiedenmann B. Novel therapeutic agents for the treatment of gastroenteropancreatic neuroendocrine tumors. Horm Metab Res, 2011, 43(12): 844-853.
24.	Bajetta E, Catena L, Procopio G, et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol, 2007, 59(5): 637-642.
25.	Okita NT, Kato K, Takahari D, et al. Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma. Gastric Cancer, 2011, 14(2): 161-165.

1. Pearse AG. The diffuse neuroendocrine system and the apud concept: related “endocrine” peptides in brain, intestine, pituitary, placenta, and anuran cutaneous glands. Med Biol, 1977, 55(3): 115-125.
2. Inzani F, Petrone G, Fadda G, et al. Cyto-histology in NET: what is necessary today and what is the future? Rev Endocr Metab Disord, 2017, 18(4): 381-391.
3. 盛伟琪. 胃肠胰神经内分泌肿瘤病理诊断的规范和进展. 中国癌症杂志, 2013, 23(6): 401-407.
4. 2013 年中国胃肠胰神经内分泌肿瘤病理诊断共识专家组. 中国胃肠胰神经内分泌肿瘤病理诊断共识 (2013 版). 中华病理学杂志, 2013, 42(10): 691-694.
5. Tan EH, Tan CH. Imaging of gastroenteropancreatic neuroendocrine tumors. World J Clin Oncol, 2011, 2(1): 28-43.
6. 徐建明. 重视对胃肠胰腺神经内分泌肿瘤的认识. 中华肿瘤杂志, 2012, 34(2): 158-160.
7. Öberg KE. Gastrointestinal neuroendocrine tumors. Ann Oncol, 2010, 21(Suppl 7): 72-80.
8. 中国临床肿瘤学会神经内分泌肿瘤专家委员会. 中国胃肠胰神经内分泌肿瘤专家共识(2016年版). 临床肿瘤学杂志, 2016, 21(10): 927-946.
9. 张太平, 李建, 赵玉沛. 胰腺神经内分泌肿瘤诊治进展. 中华外科杂志, 2014, 52(9): 706-708.
10. 刘毫, 吴诚义, 吕忠柱. 胰腺神经内分泌肿瘤的综合治疗. 中国普外基础与临床杂志, 2016, 23(3): 369-373.
11. 岑超平, 陈晓, 李冲, 等. 胰腺神经内分泌肿瘤诊治进展. 肿瘤基础与临床, 2015, 28(2): 178-179, 180.
12. Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol, 2018, 31(12): 1770-1786.
13. 李洁, 孙宇, 吴佳怿. 胰腺和胃肠道来源神经内分泌肿瘤分类—2018 IARC/WHO分类框架共识解读. 肿瘤综合治疗电子杂志, 2018, 4(4): 16-20.
14. Scoazec JY, Couvelard A, Réseau TENpath. Classification of pancreatic neuroendocrine tumours: changes made in the 2017 WHO classification of tumours of endocrine organs and perspectives for the future. Ann Pathol, 2017, 37(6): 444-456.
15. 郭鑫, 任思谦, 原春辉. 胰腺神经内分泌肿瘤综合诊治进展. 临床外科杂志, 2019, 27(12): 1094-1098.
16. Inzani F, Petrone G, Rindi G. The new World Health Organization classification for pancreatic neuroendocrine neoplasia. Endocrinol Metab Clin North Am, 2018, 47(3): 463-470.
17. 王旭, 于鑫淼, 毛晓韵, 等. 乳腺神经内分泌癌的诊断及治疗. 中国实用外科杂志, 2016, 36(7): 743-747.
18. Halvorson SA, Gilbert E, Hopkins RS, et al. Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome. J Gen Intern Med, 2013, 28(11): 1525-1529.
19. 程悦, 黄子星, 宋彬. 胰腺神经内分泌肿瘤影像研究现状及进展. 中国普外基础与临床杂志, 2020, 27(4): 489-493.
20. Moertel CG, Kvols LK, O’Connell MJ, et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer, 1991, 68(2): 227-232.
21. Yalcin S. Advances in the systemic treatment of pancreatic neuroendocrine tumors. Cancer Treat Rev, 2011, 37(2): 127-132.
22. Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC Study. Ann Oncol, 2013, 24(1): 152-160.
23. Pavel ME, Wiedenmann B. Novel therapeutic agents for the treatment of gastroenteropancreatic neuroendocrine tumors. Horm Metab Res, 2011, 43(12): 844-853.
24. Bajetta E, Catena L, Procopio G, et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol, 2007, 59(5): 637-642.
25. Okita NT, Kato K, Takahari D, et al. Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma. Gastric Cancer, 2011, 14(2): 161-165.

Previous Article
Right follicular thyroid carcinoma with metastases of cervical, mediastinum, axillary lymph nodes, and bilateral lungs: a case report

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Multiple neuroendocrine carcinoma: a case report

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content